B7-H3
Note
B7-H3 타겟 임상시험 모니터링
Visual Summary
Change History
- 2026-06-24 14:40:25: Changes detected in 4 trials: NCT04185038, NCT04637503, NCT06330064, NCT07509034
- 2026-06-09 03:56:54: Changes detected in 1 trials: NCT06158139
- 2026-06-08 04:26:42: Changes detected in 1 trials: NCT07099898
- 2026-06-02 04:24:23: Changes detected in 1 trials: NCT05942456
- 2026-05-30 03:51:21: Changes detected in 1 trials: NCT04465643
- 2026-05-26 02:58:43: Changes detected in 9 trials: NCT06500819, NCT04897321, NCT05835687, NCT06347068, NCT05241392, NCT05366179, NCT07172958, NCT05752877, NCT06305299
- 2026-04-08 02:53:25: Changes detected in 1 trials: NCT05474378
- 2026-04-07 02:52:54: Changes detected in 1 trials: NCT06778603
- 2026-03-28 02:42:32: Changes detected in 1 trials: NCT07189871
- 2026-03-20 02:30:50: Changes detected in 1 trials: NCT06158139
NCT04465643
- 2026-07-28 00:26:04 (Trial Update)
- Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-07`
- Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-27` to `2026-07-09`
- Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-29` to `2026-07-10`
- 2026-05-30 03:31:20 (Trial Update)
- Field `statusModule.statusVerifiedDate` changed from `2025-10` to `2026-05`
- Field `statusModule.lastUpdateSubmitDate` changed from `2025-10-02` to `2026-05-27`
- Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-08` to `2026-05-29`
- Field `outcomesModule.primaryOutcomes.[3]measure` changed from `Feasibility of combination nivolumab and ipilimumab as assessed by number of participants who achieve a response` to `Feasibility of combination nivolumab and ipilimumab as assessed by number of participants who start standard of care within standard treatment window`
- Field `outcomesModule.primaryOutcomes.[3]description` changed from `Number of participants who achieve a response (improved progression free survival).` to `Number of participants who start standard of care treatment within 8 week`
- Field `outcomesModule.primaryOutcomes.[3]timeFrame` changed from `Up to 2 years` to `Up to 8 weeks`
📥 Download Full Data (CSV) 📥 Download Status Summary (CSV)
Monitoring Status
| Trial ID | Sponsor | Update | Status | Conditions | Phases | Start | End | Enroll | Last Updated |
|---|---|---|---|---|---|---|---|---|---|
| NCT07358260 | Robbie Majzner | No Change | Not Yet Recruiting | Pediatric Solid Tumor, Neurobl… | PHASE1 | 2026-06 | 2031-12-31 | 40 | 2026-01-14 |
| NCT06500819 | Stanford University | Changed | Recruiting | Neuroblastoma, Sarcoma, Osteos… | PHASE1 | 2024-07-11 | 2029-07 | 41 | 2026-05-01 |
| NCT05515185 | The First People's Hospital of… | No Change | Unknown | Advanced Solid Tumor | EARLY_PHASE1 | 2022-09-09 | 2024-09-08 | 30 | 2022-08-23 |
| NCT06778603 | Peking University People's Hos… | No Change | Recruiting | Osteosarcoma, Resection Margin… | PHASE1 PHASE2 | 2024-01-01 | 2026-12-31 | 32 | 2025-01-11 |
| NCT05942456 | Peking University People's Hos… | Changed | Unknown | Biomarker, Progression, Osteos… | N/A | 2023-06-05 | 2024-12-31 | 200 | 2024-05-11 |
| NCT04077866 | Second Affiliated Hospital, Sc… | No Change | Unknown | Recurrent Glioblastoma, Refrac… | PHASE1 PHASE2 | 2023-06-01 | 2025-08-01 | 40 | 2022-12-25 |
| NCT05474378 | Stanford University | No Change | Recruiting | Brain and Nervous System | PHASE1 | 2022-07-12 | 2026-08 | 39 | 2026-04-01 |
| NCT04897321 | St. Jude Children's Research H… | Changed | Recruiting | Pediatric Solid Tumor, Osteosa… | PHASE1 | 2022-07-06 | 2028-03-01 | 48 | 2026-05-18 |
| NCT06158139 | UNC Lineberger Comprehensive C… | Changed | Recruiting | Pancreas Cancer, Relapse, Resi… | PHASE1 | 2024-07-18 | 2030-04 | 27 | 2026-06-05 |
| NCT04385173 | Second Affiliated Hospital, Sc… | No Change | Unknown | Recurrent Glioblastoma, Refrac… | PHASE1 | 2022-12-01 | 2024-05-01 | 12 | 2022-12-25 |
| NCT05835687 | St. Jude Children's Research H… | Changed | Recruiting | Central Nervous System Neoplas… | PHASE1 | 2023-04-27 | 2028-03 | 48 | 2026-05-01 |
| NCT02628535 | MacroGenics | No Change | Terminated | Mesothelioma, Bladder Cancer, … | PHASE1 | 2015-09 | 2019-11-25 | 67 | 2022-02-04 |
| NCT07222735 | St. Jude Children's Research H… | No Change | Recruiting | Sarcoma, Childhood Osteosarcom… | PHASE1 | 2026-01-21 | 2031-11-05 | 42 | 2026-02-06 |
| NCT06018363 | Dushu Lake Hospital Affiliated… | No Change | Recruiting | Brain Gliomas, High-Grade Glio… | PHASE1 PHASE2 | 2023-06-01 | 2027-12-31 | 25 | 2025-08-13 |
| NCT06646627 | Stanford University | No Change | Recruiting | Ovarian Cancer | PHASE1 | 2024-11-11 | 2026-07 | 48 | 2026-02-05 |
| NCT06347068 | UNC Lineberger Comprehensive C… | Changed | Recruiting | Breast Cancer, Relapse, Resist… | PHASE1 | 2024-06-27 | 2028-05 | 42 | 2026-04-17 |
| NCT04432649 | Shenzhen Geno-Immune Medical I… | Changed | Recruiting | Solid Tumor | PHASE1 PHASE2 | 2026-06-01 | 2030-12-31 | 100 | 2026-06-18 |
| NCT02982941 | MacroGenics | No Change | Completed | Neuroblastoma, Rhabdomyosarcom… | PHASE1 | 2016-12 | 2019-05-22 | 25 | 2022-02-04 |
| NCT05562024 | PersonGen BioTherapeutics (Suz… | No Change | Recruiting | B7-H3-positive Relapsed/ Refra… | PHASE1 | 2022-12-30 | 2039-02-18 | 24 | 2023-02-23 |
| NCT04670068 | UNC Lineberger Comprehensive C… | No Change | Active Not Recruiting | Epithelial Ovarian Cancer | PHASE1 | 2021-01-27 | 2030-02 | 4 | 2025-12-04 |
| NCT05241392 | Beijing Tiantan Hospital | Changed | Active Not Recruiting | Glioblastoma | PHASE1 | 2022-01-27 | 2026-12-31 | 30 | 2026-04-28 |
| NCT03406949 | MacroGenics | No Change | Completed | Advanced Solid Tumors | PHASE1 | 2018-02-27 | 2022-04-27 | 25 | 2022-05-18 |
| NCT05366179 | UNC Lineberger Comprehensive C… | Changed | Recruiting | Glioblastoma Multiforme | PHASE1 | 2022-09-02 | 2030-05-30 | 36 | 2026-04-16 |
| NCT07172958 | Children's National Research I… | Changed | Recruiting | Rhabdomyosarcoma, Ewing Sarcom… | PHASE1 | 2026-01-27 | 2038-12 | 18 | 2026-05-20 |
| NCT06454955 | Peking University Cancer Hospi… | No Change | Recruiting | B7H3, CD276 Affibody, PET/CT I… | EARLY_PHASE1 | 2024-01-01 | 2026-11-30 | 50 | 2024-08-21 |
| NCT05752877 | Second Affiliated Hospital of … | Changed | Unknown | Advanced Glioma, Complication … | NA | 2021-05-01 | 2026-04-30 | 12 | 2023-03-02 |
| NCT05190185 | PersonGen BioTherapeutics (Suz… | No Change | Unknown | Malignant Melanoma, Lung Cance… | PHASE1 | 2021-06-01 | 2023-12-01 | 18 | 2021-12-29 |
| NCT03198052 | Second Affiliated Hospital of … | No Change | Recruiting | Lung Cancer, Cancer, Immunothe… | PHASE1 | 2017-07-01 | 2036-08-01 | 30 | 2024-06-22 |
| NCT06951243 | Beijing GoBroad Hospital | No Change | Not Yet Recruiting | Advanced Extrapulmonary Neuroe… | PHASE2 | 2025-05-06 | 2028-05-06 | 40 | 2025-04-22 |
| NCT06305299 | UNC Lineberger Comprehensive C… | Changed | Recruiting | Ovary Neoplasm, Ovarian Cancer… | PHASE1 | 2024-07-29 | 2036-04 | 27 | 2026-05-14 |
| NCT07189871 | Radiopharm Theranostics, Ltd | No Change | Recruiting | Castration-Resistant Prostate … | PHASE1 PHASE2 | 2026-02-23 | 2027-12 | 61 | 2026-03-24 |
| NCT05731219 | PersonGen BioTherapeutics (Suz… | No Change | Unknown | Relapsed/Refractory Acute Myel… | PHASE1 | 2022-09-26 | 2025-09-26 | 18 | 2023-02-15 |
| NCT06169904 | Shanghai Zhongshan Hospital | No Change | Completed | Urothelial Carcinoma | N/A | 2012-01-25 | 2022-11-22 | 215 | 2023-12-12 |
| NCT02381314 | MacroGenics | No Change | Completed | Melanoma, Non Small Cell Lung … | PHASE1 | 2015-03-26 | 2018-09-26 | 24 | 2022-02-04 |
| NCT01918930 | MacroGenics | No Change | Terminated | Melanoma | PHASE1 | 2013-07 | 2016-10 | 6 | 2022-02-04 |
| NCT05722171 | PersonGen BioTherapeutics (Suz… | No Change | Unknown | Relapsed/Refractory Acute Myel… | EARLY_PHASE1 | 2022-12-27 | 2024-12-27 | 10 | 2023-01-31 |
| NCT07268053 | Nader Sanai | No Change | Recruiting | Glioblastoma (GBM), Brain Meta… | EARLY_PHASE1 | 2026-02-11 | 2029-07 | 15 | 2026-03-04 |
| NCT05143151 | Shenzhen University General Ho… | No Change | Unknown | Advanced Pancreatic Carcinoma | PHASE1 PHASE2 | 2021-07-01 | 2024-07 | 10 | 2021-12-02 |
| NCT04315246 | Y-mAbs Therapeutics | No Change | Withdrawn | Leptomeningeal Metastasis, Sol… | PHASE1 PHASE2 | 2022-08-31 | 2024-12-31 | 0 | 2022-07-12 |
| NCT04185038 | Seattle Children's Hospital | Changed | Recruiting | Central Nervous System Tumor, … | PHASE1 | 2019-12-11 | 2042-05 | 90 | 2026-04-07 |
| NCT07099898 | GlaxoSmithKline | Changed | Recruiting | Neoplasms, Lung | PHASE3 | 2025-08-11 | 2029-09-28 | 420 | 2026-05-22 |
| NCT04167618 | Y-mAbs Therapeutics | No Change | Terminated | Medulloblastoma, Childhood | PHASE1 PHASE2 | 2021-09-30 | 2022-08-11 | 2 | 2023-09-11 |
| NCT05768880 | Seattle Children's Hospital | No Change | Active Not Recruiting | Diffuse Intrinsic Pontine Glio… | PHASE1 | 2023-05-05 | 2043-12-31 | 72 | 2025-11-17 |
| NCT06699576 | Hansoh BioMedical R&D Company | No Change | Not Yet Recruiting | Osteosarcoma, Soft Tissue Sarc… | PHASE1 | 2024-12-20 | 2028-12-30 | 448 | 2024-11-19 |
| NCT06825624 | Hansoh BioMedical R&D Company | No Change | Recruiting | Metastatic Colorectal Cancer (… | PHASE1 | 2024-10-03 | 2026-12-31 | 560 | 2025-02-09 |
| NCT06112704 | Hansoh BioMedical R&D Company | No Change | Recruiting | Advanced Solid Tumor | PHASE2 | 2024-02-06 | 2026-12-31 | 220 | 2024-11-27 |
| NCT05280470 | Daiichi Sankyo | Changed | Active Not Recruiting | Extensive-stage Small-cell Lun… | PHASE2 | 2022-03-09 | 2026-12-15 | 187 | 2026-02-23 |
| NCT06912152 | Zhejiang University | No Change | Recruiting | B7-H3-positive Advanced Malign… | PHASE1 | 2025-05-12 | 2028-12-31 | 12 | 2025-05-19 |
| NCT06426680 | Innolake Biopharm | No Change | Recruiting | Advanced Solid Tumor | PHASE1 | 2024-10-30 | 2026-03 | 240 | 2024-12-04 |
| NCT02475213 | MacroGenics | No Change | Completed | Melanoma, Head and Neck Cancer… | PHASE1 | 2015-07 | 2021-08-18 | 146 | 2025-08-04 |
| NCT06482905 | Tcelltech Inc. | Changed | Recruiting | High-grade Glioma, WHO Grade Ⅳ… | PHASE1 | 2024-09-04 | 2027-06 | 52 | 2026-03-19 |
| NCT06892548 | BioNTech SE | Changed | Recruiting | Advanced Lung Cancer | PHASE1 PHASE2 | 2025-05-02 | 2031-06 | 594 | 2026-05-18 |
| NCT04129320 | MacroGenics | No Change | Withdrawn | Head and Neck Cancer, Squamous… | PHASE2 PHASE3 | 2019-10 | 2022-10 | 0 | 2022-02-04 |
| NCT07256782 | Qilu Pharmaceutical Co., Ltd. | No Change | Recruiting | Advanced Solid Tumor | PHASE1 PHASE2 | 2025-10-24 | 2028-05 | 444 | 2025-11-25 |
| NCT03729596 | MacroGenics | No Change | Terminated | Squamous Cell Carcinoma of Hea… | PHASE1 PHASE2 | 2018-11-21 | 2023-03-18 | 143 | 2025-07-10 |
| NCT06332170 | Hansoh BioMedical R&D Company | No Change | Recruiting | Advanced Solid Tumor | PHASE1 | 2024-04-26 | 2028-05-30 | 610 | 2024-07-16 |
| NCT05830123 | Hansoh BioMedical R&D Company | No Change | Recruiting | Osteosarcoma, Sarcoma | PHASE2 | 2023-06-08 | 2027-12-31 | 170 | 2024-08-22 |
| NCT02456571 | Duke University | No Change | Completed | Prostate Cancer | N/A | 2016-11 | 2019-06-13 | 38 | 2019-07-08 |
| NCT07115446 | Hansoh BioMedical R&D Company | No Change | Recruiting | Advanced Prostate Cancer | PHASE1 | 2025-08-19 | 2028-12 | 63 | 2025-11-28 |
| NCT06203210 | Daiichi Sankyo | Changed | Recruiting | Small Cell Lung Cancer | PHASE3 | 2024-05-21 | 2029-02-22 | 540 | 2026-05-29 |
| NCT06007729 | Hansoh BioMedical R&D Company | No Change | Recruiting | Head and Neck Squamous Cell Ca… | PHASE2 | 2023-12-18 | 2027-12-12 | 170 | 2024-08-19 |
| NCT04637503 | Shenzhen Geno-Immune Medical I… | Changed | Recruiting | Neuroblastoma | PHASE1 PHASE2 | 2026-06-01 | 2030-12-31 | 100 | 2026-06-18 |
| NCT06052423 | Hansoh BioMedical R&D Company | No Change | Withdrawn | Extensive Stage Small Cell Lun… | PHASE2 | 2024-11-30 | 2027-06-30 | 0 | 2024-03-01 |
| NCT06242470 | MacroGenics | No Change | Recruiting | Advanced Solid Tumor, Advanced… | PHASE1 | 2024-03-06 | 2028-10 | 250 | 2026-02-03 |
| NCT06780137 | Merck Sharp & Dohme LLC | Changed | Recruiting | Small Cell Lung Cancer | PHASE1 PHASE2 | 2025-02-27 | 2030-01-17 | 262 | 2026-04-17 |
| NCT05276609 | Shanghai Hansoh Biomedical Co…. | No Change | Unknown | Advanced Solid Tumor | PHASE1 | 2021-11-28 | 2023-12-31 | 177 | 2023-02-13 |
| NCT07227597 | Merck Sharp & Dohme LLC | Changed | Recruiting | Small Cell Lung Cancer Extensi… | PHASE1 PHASE2 | 2026-01-29 | 2030-12-30 | 170 | 2026-06-10 |
| NCT07386002 | T-MAXIMUM Pharmaceutical Inc | Changed | Not Yet Recruiting | Glioblastoma IDH (Isocitrate D… | PHASE2 | 2026-06-30 | 2029-07-31 | 40 | 2026-02-06 |
| NCT05063357 | Y-mAbs Therapeutics | No Change | Withdrawn | DIPG | PHASE1 | 2022-03 | 2026-12 | 0 | 2023-06-22 |
| NCT06776198 | Peking University People's Hos… | No Change | Not Yet Recruiting | Osteosarcoma, Transcriptome, T… | N/A | 2025-03-01 | 2027-06-01 | 100 | 2025-01-21 |
| NCT04842812 | Second Affiliated Hospital of … | No Change | Recruiting | Liver Cancer, Lung Cancer, Bre… | PHASE1 | 2021-01-01 | 2035-01-01 | 40 | 2024-06-22 |
| NCT06001255 | Hansoh BioMedical R&D Company | Changed | Recruiting | Metastasis Castration Resistan… | PHASE2 | 2024-01-18 | 2025-12-31 | 120 | 2024-08-19 |
| NCT06330064 | Daiichi Sankyo | Changed | Recruiting | Recurrent or Metastatic Solid … | PHASE2 | 2024-04-10 | 2028-07-25 | 520 | 2026-02-10 |
| NCT07231081 | Tcelltech Inc. | No Change | Recruiting | Solid Tumors | PHASE1 | 2025-10-16 | 2027-12-20 | 85 | 2025-11-13 |
| NCT05064306 | Memorial Sloan Kettering Cance… | No Change | No Longer Available | Central Nervous System/Leptome… | N/A | N/A | N/A | N/A | 2025-07-29 |
| NCT05142189 | BioNTech SE | Changed | Recruiting | Non-Small Cell Lung Cancer | PHASE1 | 2022-06-17 | 2031-11 | 320 | 2026-04-09 |
| NCT06362252 | Daiichi Sankyo | No Change | Recruiting | Extensive Stage-small Cell Lun… | PHASE1 PHASE2 | 2024-07-22 | 2026-12-30 | 123 | 2026-02-04 |
| NCT06372236 | Peking University | No Change | Completed | Conditions or Focus of Study: … | PHASE1 | 2023-12-05 | 2025-05-08 | 10 | 2025-08-07 |
| NCT06954246 | Qilu Pharmaceutical Co., Ltd. | No Change | Recruiting | Small Cell Lung Cancer Extensi… | PHASE3 | 2025-06-04 | 2028-04 | 450 | 2025-06-15 |
| NCT04634825 | MacroGenics | No Change | Terminated | Head and Neck Cancer, Head and… | PHASE2 | 2021-03-17 | 2022-07-29 | 62 | 2023-12-18 |
| NCT05991583 | SUNHO（China）BioPharmaceutical … | No Change | Recruiting | Advanced Malignant Tumors | PHASE1 PHASE2 | 2023-07-03 | 2025-12-30 | 25 | 2025-01-15 |
| NCT07076095 | SUNHO（China）BioPharmaceutical … | No Change | Not Yet Recruiting | Small Cell Lung Cancer | PHASE2 | 2025-08-01 | 2031-08-01 | 200 | 2025-07-17 |
| NCT04864821 | PersonGen BioTherapeutics (Suz… | No Change | Unknown | Osteosarcoma, Neuroblastoma, G… | EARLY_PHASE1 | 2021-05-14 | 2023-05-14 | 24 | 2021-04-30 |
| NCT05914116 | DualityBio Inc. | Changed | Recruiting | Advanced Solid Tumors | PHASE1 PHASE2 | 2023-08-17 | 2028-05 | 862 | 2025-11-18 |
| NCT07004647 | Ruijin Hospital | No Change | Recruiting | Peritoneal Tumor | NA | 2025-03-15 | 2028-11-30 | 10 | 2025-05-26 |
| NCT07181473 | Phrontline Biopharma | No Change | Recruiting | Lung Cancer (NSCLC), Prostate … | PHASE1 | 2025-08-25 | 2027-09-15 | 200 | 2026-01-08 |
| NCT05293496 | MacroGenics | No Change | Completed | Advanced Solid Tumor, Castrati… | PHASE1 | 2022-04-19 | 2025-08-26 | 31 | 2025-10-09 |
| NCT06742593 | Suzhou Maximum Bio-tech Co., L… | No Change | Not Yet Recruiting | Brain (Nervous System) Cancers… | PHASE1 | 2025-01-01 | 2026-12-30 | 12 | 2024-12-17 |
| NCT04630769 | Masonic Cancer Center, Univers… | No Change | Completed | Ovarian Cancer, Fallopian Tube… | PHASE1 | 2021-04-02 | 2022-01-01 | 3 | 2023-03-27 |
| NCT04544592 | University of Colorado, Denver | Changed | Recruiting | B-cell Acute Lymphoblastic Leu… | PHASE1 PHASE2 | 2021-03-10 | 2026-07 | 45 | 2026-04-16 |
| NCT02883595 | Sun Yat-sen University | No Change | Completed | Sepsis | PHASE4 | 2016-03-31 | 2016-12-31 | 20 | 2019-04-02 |
| NCT00554515 | Beth Israel Deaconess Medical … | No Change | Completed | Metastatic Renal Cell Carcinom… | PHASE2 | 2006-11 | 2013-10-31 | 123 | 2024-08-07 |
| NCT02204020 | University of Pittsburgh | No Change | Withdrawn | Acute Myeloid Leukemia (AML), … | PHASE2 | 2015-04 | 2016-05-04 | 0 | 2018-03-29 |
| NCT02937844 | Beijing Sanbo Brain Hospital | No Change | Unknown | Glioblastoma Multiforme | PHASE1 | 2016-07 | 2019-07 | 20 | 2016-10-17 |
| NCT06644781 | Daiichi Sankyo | No Change | Recruiting | Esophageal Squamous Cell Carci… | PHASE3 | 2025-03-27 | 2029-11-01 | 510 | 2026-01-09 |
| NCT05562869 | Nantes University Hospital | No Change | Recruiting | Chronic Kidney Failure | PHASE3 | 2024-05-03 | 2027-05-03 | 30 | 2024-05-07 |
| NCT04013620 | Nantes University Hospital | No Change | Unknown | Chronic Kidney Failure | PHASE3 | 2020-09-01 | 2022-07-09 | 48 | 2020-03-30 |
| NCT04276701 | University Hospital, Bordeaux | No Change | Active Not Recruiting | Systemic Lupus Erythematosus | NA | 2021-03-10 | 2027-03 | 500 | 2026-01-30 |
| NCT07136558 | Beijing InnoCare Pharma Tech C… | No Change | Not Yet Recruiting | Advanced Solid Tumors | PHASE1 | 2025-08 | 2030-12 | 410 | 2025-08-20 |
| NCT06953089 | DualityBio Inc. | Changed | Recruiting | Solid Tumors | PHASE2 | 2025-07-18 | 2030-06-30 | 450 | 2026-05-20 |
| NCT02584517 | University of Oxford | No Change | Withdrawn | Temporal Arteritis | N/A | 2016-01 | 2021-01 | 0 | 2022-08-10 |
| NCT07307053 | Cancer Institute and Hospital,… | No Change | Not Yet Recruiting | Rare Malignant Neoplasm, Advan… | PHASE1 PHASE2 | 2026-01-01 | 2031-01-31 | 600 | 2025-12-13 |
| NCT06993766 | King Faisal Specialist Hospita… | No Change | Not Yet Recruiting | Relapsed B-ALL, CAR T-cells, C… | N/A | 2025-05-20 | 2030-05-31 | 100 | 2025-05-19 |
| NCT02923180 | Sidney Kimmel Comprehensive Ca… | No Change | Active Not Recruiting | Prostate Cancer | PHASE2 | 2017-02-14 | 2026-07 | 33 | 2025-07-10 |
| NCT06014255 | Sidney Kimmel Comprehensive Ca… | No Change | Recruiting | Prostate Cancer | PHASE2 | 2024-02-16 | 2029-03-01 | 219 | 2025-10-28 |
| NCT04465643 | Sidney Kimmel Comprehensive Ca… | Changed | Completed | Nerve Sheath Tumors | PHASE1 | 2021-06-08 | 2025-07-30 | 13 | 2026-05-27 |
| NCT06221553 | Chulalongkorn University | No Change | Recruiting | DIPG Brain Tumor, Diffuse Intr… | PHASE1 | 2024-03-01 | 2026-09-01 | 9 | 2025-03-27 |
| NCT06612645 | Chulalongkorn University | No Change | Recruiting | Pediatric Cancers, Solid Tumor… | PHASE1 | 2025-04-01 | 2028-12-01 | 9 | 2026-02-26 |
| NCT04514484 | National Cancer Institute (NCI… | Changed | Active Not Recruiting | Advanced Differentiated Thyroi… | PHASE1 | 2021-11-22 | 2027-02-06 | 8 | 2026-05-08 |
| NCT04743661 | Pediatric Brain Tumor Consorti… | No Change | Active Not Recruiting | Recurrent Medulloblastoma, Rec… | PHASE2 | 2022-04-04 | 2027-09-30 | 62 | 2026-02-03 |
| NCT03014804 | Jonsson Comprehensive Cancer C… | No Change | Withdrawn | Giant Cell Glioblastoma, Glios… | PHASE2 | 2019-12-01 | 2022-12-01 | 0 | 2020-07-22 |
| NCT07428993 | St. Jude Children's Research H… | Changed | Recruiting | Pediatric Osteosarcoma | PHASE2 | 2026-06 | 2035-12 | 41 | 2026-05-18 |
| NCT07423117 | IntoCell, Inc | No Change | Not Yet Recruiting | Metastatic Castration-resistan… | PHASE1 | 2026-02-06 | 2029-12-31 | 102 | 2026-02-18 |
| NCT07415863 | CSPC Megalith Biopharmaceutica… | No Change | Recruiting | Advanced/Metastatic Solid Tumo… | PHASE1 PHASE2 | 2024-12-30 | 2028-06-30 | 820 | 2026-02-10 |
| NCT07462923 | Hansoh BioMedical R&D Company | No Change | Recruiting | Advanced Gastric and Gastroeso… | PHASE1 | 2026-01-29 | 2028-03-31 | 40 | 2026-03-06 |
| NCT07408063 | University Health Network, Tor… | Changed | Recruiting | Recurrent/Metastatic Head and … | PHASE2 | 2026-04-27 | 2031-03-01 | 30 | 2026-04-28 |
| NCT07390539 | Robbie Majzner | No Change | Not Yet Recruiting | Central Nervous System Neoplas… | PHASE1 | 2026-07 | 2032-08-31 | 70 | 2026-01-28 |
| NCT07424547 | Conjupro Biotherapeutics, Inc. | Changed | Recruiting | Cancer, Solid Tumor Cancer, Ad… | PHASE1 | 2026-03-03 | 2030-04 | 386 | 2026-04-06 |
| NCT07597369 | Peking University First Hospit… | Changed | Active Not Recruiting | Prostate Cancer, Metastatic Pr… | N/A | 2026-01-01 | 2029-01-01 | 1,600 | 2026-06-11 |
| NCT07541534 | Shanghai Henlius Biotech | Changed | Recruiting | Advanced/Metastatic Solid Tumo… | PHASE1 | 2026-05-22 | 2029-06-01 | 41 | 2026-05-25 |
| NCT07502287 | Beijing Biotech | No Change | Recruiting | Relapsed Neuroblastoma, Refrac… | PHASE1 PHASE2 | 2026-03-02 | 2028-06-17 | 36 | 2026-03-25 |
| NCT07523529 | Beijing Biotech | No Change | Recruiting | Advanced Unresectable, Metasta… | PHASE1 PHASE2 | 2026-03-02 | 2028-03-17 | 72 | 2026-04-05 |
| NCT07503808 | IDEAYA Biosciences | Changed | Recruiting | Esophageal Squamous Cell Carci… | PHASE1 | 2026-02-24 | 2027-07-30 | 150 | 2026-06-16 |
| NCT07541573 | Masonic Cancer Center, Univers… | No Change | Recruiting | Tri-specific Killer Engager, S… | PHASE1 | 2026-04-08 | 2032-01 | 175 | 2026-04-20 |
| NCT07551336 | Beijing Biotech | No Change | Recruiting | Malignant Glioma, High-Grade G… | PHASE1 | 2026-03-02 | 2028-04-17 | 36 | 2026-04-18 |
| NCT07581184 | Aktis Oncology, Inc. | No Change | Recruiting | Castration Resistant Metastati… | PHASE1 | 2026-07 | 2032-06 | 138 | 2026-05-06 |
| NCT07515313 | Assiut University | No Change | Not Yet Recruiting | B-cell Malignancies | N/A | 2026-07-01 | 2030-12-01 | 159 | 2026-03-31 |
| NCT07480941 | Beijing Biotech | No Change | Recruiting | Glioblastoma, High-grade Gliom… | PHASE1 | 2026-02-02 | 2028-03-17 | 36 | 2026-03-14 |
| NCT07509034 | National Cancer Institute (NCI… | Changed | Not Yet Recruiting | Extensive-Stage Small Cell Lun… | PHASE1 | 2026-06-28 | 2031-01-30 | 40 | 2026-06-22 |
| NCT07500220 | Beijing Biotech | No Change | Recruiting | Advanced Hepatocellular Carcin… | PHASE1 PHASE2 | 2026-03-02 | 2028-03-17 | 30 | 2026-03-24 |
| NCT07612176 | NEOK Bio, Inc. | No Change | Recruiting | Locally Advanced (Unresectable… | PHASE1 | 2026-04-21 | 2029-01 | 155 | 2026-05-21 |